Ashlesh Dani, MD
Neurology · Fishkill, NYNPI 1568560779
Payments from drug & device makers
Across 58 payments — averaging $243.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Pfizer$170
- AstraZeneca$169
- EMD Serono, Inc.$111
- Genentech USA, Inc.$78
- Boston Scientific$74
- plus $205 from 8 others
What the payments were for
- Speaking & faculty fees$11,33080%
- Travel & lodging$1,2529%
- Food & beverage$1,51611%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $13,333 |
| Pfizer | 5 | $170 |
| AstraZeneca | 2 | $169 |
| EMD Serono, Inc. | 1 | $111 |
| Genentech USA, Inc. | 1 | $78 |
| Boston Scientific | 3 | $74 |
| UCB, Inc. | 3 | $52 |
| Biogen | 1 | $42 |
| Servier Pharmaceuticals LLC | 2 | $33 |
| Lundbeck LLC | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,140 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 47 | $41,599 |
| Memantine Hcl | 88 | $4,529 |
| Gabapentin | 95 | $1,420 |
| Levetiracetam | 50 | $1,220 |
| Lacosamide | 14 | $1,168 |
| Pregabalin | 24 | $1,142 |
| Duloxetine Hcl | 19 | $1,036 |
| Oxcarbazepine | 12 | $977 |
| Donepezil Hcl | 107 | $915 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 24 | $907 |
| Primidone | 34 | $676 |
| Quetiapine Fumarate | 19 | $613 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 28 | $365 |
| Nortriptyline Hcl | 25 | $364 |
| Topiramate | 29 | $327 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fishkill
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
- Krupa PandeyAlbany$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.